CD274 and esophageal squamous cell carcinoma: Studies such as the ATTRACTION-3 trial have demonstrated that ICIs have shown promising results in previously treated advanced ESCC patients, irrespective of tumor programmed death-ligand 1 (PD-L1) expression [9].